Intriguingly, the correlations of olaparib sensitivities with transcriptome-wide mRNA expression in breast cancer cell lines revealed that the PRMT1 gene was within the top ranks (Figure 1A), and breast cancer cells with an elevated expression of PRMT1 were associated with therapeutic resistance to olaparib (Figure 1B). The gene discussed is PRMT1; the disease is breast carcinoma.